Swiss National Bank Acquires 13,700 Shares of United Therapeutics Corporation (UTHR)

Swiss National Bank grew its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 9.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 164,000 shares of the biotechnology company’s stock after acquiring an additional 13,700 shares during the period. Swiss National Bank owned about 0.38% of United Therapeutics Corporation worth $21,276,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Focused Wealth Management Inc boosted its holdings in shares of United Therapeutics Corporation by 17.5% in the 1st quarter. Focused Wealth Management Inc now owns 940 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 140 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of United Therapeutics Corporation by 17.4% in the 1st quarter. Daiwa Securities Group Inc. now owns 1,350 shares of the biotechnology company’s stock valued at $183,000 after acquiring an additional 200 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new stake in shares of United Therapeutics Corporation in the 1st quarter valued at $204,000. Eagle Global Advisors LLC purchased a new stake in shares of United Therapeutics Corporation in the 2nd quarter valued at $206,000. Finally, Clarity Capital KCPS Ltd. purchased a new stake in shares of United Therapeutics Corporation in the 1st quarter valued at $230,000.

COPYRIGHT VIOLATION WARNING: “Swiss National Bank Acquires 13,700 Shares of United Therapeutics Corporation (UTHR)” was published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.themarketsdaily.com/2017/09/11/swiss-national-bank-acquires-13700-shares-of-united-therapeutics-corporation-uthr.html.

UTHR has been the topic of several recent research reports. Zacks Investment Research downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Thursday, July 13th. BidaskClub downgraded shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a report on Monday, July 31st. ValuEngine raised shares of United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 13th. UBS AG reaffirmed a “sell” rating and issued a $106.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, July 6th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and issued a $105.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, June 8th. Six analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have assigned a buy rating to the company. United Therapeutics Corporation has an average rating of “Hold” and an average target price of $134.50.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 120.82 on Monday. The stock has a market capitalization of $5.25 billion, a P/E ratio of 14.01 and a beta of 1.52. The company’s 50-day moving average is $130.10 and its 200-day moving average is $130.86. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last posted its quarterly earnings data on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter last year, the business earned $4.42 earnings per share. The business’s quarterly revenue was up 7.8% on a year-over-year basis. On average, equities research analysts anticipate that United Therapeutics Corporation will post $10.09 earnings per share for the current year.

In related news, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the transaction, the director now directly owns 3,875 shares in the company, valued at approximately $513,863.75. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Raymond Dwek sold 3,490 shares of United Therapeutics Corporation stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $131.71, for a total transaction of $459,667.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,178 shares of company stock worth $3,289,427. 7.80% of the stock is currently owned by insiders.

United Therapeutics Corporation Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply